Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells

British Journal of Cancer

Volumn 75, Issue 6, 1997, Pages 878-883

  Ghielmini, M ^a,c   Bosshard, G ^a,b   Capolongo, L ^a,c   Geroni, M C ^a,b   Pesenti, E ^a,b   Torri, V ^a,b   D'Incalci, M ^a,b   Cavalli, F ^a,c   Sessa, C ^a,b  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b PFIZER INC   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Carzelesin; Clonogenic tests; Tallimustine; Toxicology

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ANTIVIRUS AGENT; CARZELESIN; CHLORMETHINE DERIVATIVE; DISTAMYCIN A DERIVATIVE; FCE 25450; FCE 28102; FCE 28164; MELPHALAN; TALLIMUSTINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CELL; BONE MARROW CELL; BONE MARROW TOXICITY; BURST FORMING UNIT E; CLONOGENIC ASSAY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL; UMBILICAL CORD BLOOD;

EID: 0031051013     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.155     Document Type: Article

References (32)

1. Beck WT, Muelle TJ and Tanzler LR (1979) Altered surface membrane glycoproteins in vinca-alkaloid-resistant human leukemic lymphoblasts. Cancer Res 37: 5455-5460
2. Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F and D'Incalci M (1991) Sélective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res SI: 199-204
3. Collins JM, Grieshaber CK and Chabner BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. JKail Cancer Inst 82: 1321-1326
4. Coutinho LH, Gilleece MH, De Wynter EA, Will A and Testa NG (1993) Clonal and long-term cultures using human bone marrow. In Haemopoiesis. A Practical Approach, Testa NG and Molineux G (eds), pp. 75-105. Oxford University Press: New York
5. D'Alessio R, Geroni C, Biasoli G, Pesenti E, Grandi M and Mongelli N (1994) Structure-activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorganic and Medicinal Chemistry Letters 4: 1467-1472
6. D'Incalci M ( 1994) DNA-minor-groove alkylators, a new class of anticancer agents. AnnOncol S: 877-878
7. Danks MK, Yalowich JC and Beck WT (1987) Atypical muliiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301
8. Davis LE, Alberts DS, Plezia P.M, ROE DJ and Griswold DP (1988) Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients. J Nail Cancer Inst 80:815-819
9. Drewinko B, Romsdahal MM. Jang LJ, Ahearn MI and Trujillo JM (1976) Establishment of a human carcinoembrionic antigen producing colon adenocarcinoma cell line. Cancer Res 36:467
10. Du DL. Volpe DA. Grieshaber CK and Murphy MJJ ( 1990) Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro. Cancer Res 50:4038-4043
11. Du DL, Volpe DA, Grieshaber CK and Murphy MJJ ( 1991 ) Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Invest New Drugs 9: 149-157
12. Du XX, Scott D, Yang ZX, Cooper R, Xiao XL and Williams DA (1995) Interleukin-11 stimulates multilineage progenitors, but not stem cells, in murine and human long-term marrow cultures. Blood 86: 128-134
13. Eortc Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23: 1083-1087
14. Fogh J and Trempe G (1975) New human tumor cell lines. In Human Tumor Cell 'In Vitro', Fogh J (ed.), p. 115. Plenum Publishing: New York
15. Friedman DA (1981) Bootstrap regression models. Ann Slat 9: 1218-1228
16. Fritsch G, Stimpfl M, Kurz M, Printz D, Buchinger P, Fischmeister G, Hoecker P and Gadner H (1996) The composition of CD34 subpopulations differs between bone marrow, blood and cord blood. Bone Marrow Transplantation 17:169-178
17. Gianni L, Viganö L, Surbone A, Ballinari D, Casali P, Tarella C, Collins JM and Bonadonna G (1990) Pharmacology and clinical toxicity of 4′-Iodo-4′-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82: 469-477
18. Hao Q-L, Shah AJ, Thiemann FT. Smogarzewska EM and Crooks GM (1995) A functional comparison of CD34+CD38- cells in cord blood and bone marrow. Blood 86: 3745-3753
19. Hows JM, Bradley BA, Marsh JCW, Luft T, Coutinho LU, Testa NG and Dexter TM (1992) Growth of human umbilical-cord blood in longterm haemopoietic cultures. Lancet 340:73-75
20. Keating A (1987) Ph positive CML cell lines. Clin Hematol 1: 1021-1029
21. Lewis JL, Blackett NM and Gordon MY (1994) The kinetics of colony formation by CFU-GM in vitro. Br J Haematol 88: 440-442
22. Léglise MC, Darodes DE Tailly P, Vignot JL, Le Bot MA, Le Roux A-M and Riche C (1996) A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drugrelated myelosuppression of normal hematopoiesis. Cell Biol Toxicol 12: 39-53
23. Li LH, Dekoning TF, Kelly RC, Krueger WC, Mcgoveren JP, Padbury GE, Petzold GL, Wallace TL, Ouding RJ, Prairie MD and Gebhard I (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904-4913
24. Parchment RE, Huang M and Erickson-Miller CL ( 1993) Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Tmicol Paihol 21: 241-250
25. Parchment RE, Lorusso PM, Volpe DA, Erickson-Miller CL, Murphy MJJ and Grieshaber CK ( 1994) In vivo-in vitro correlation of myelotoxicity of 9methoxypyrazoloacridine (NSC-366140, PD 115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J Natl Cancer Inst 86: 273-280
26. Pezzoni G, Grandi M, Biasoli G, Capolongo L, Ballinari D, Giuliani FC, Barbieri B, Pastori A, Pesenti E, Mongelli E and Spreafico F (1991) Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br ] Cancer 64:1047-1050
27. Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bottling MK, Chen T, Lubcjko EG, Kaufmann SU and Donehosver RC (1995) Phase I and pharmacologie studies of pyrazoloacridine, a novel DMA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13: 1975-1984
28. Sessa C, Pagani O, Zurlo MG, DE Jong J, Hofmann C, Lassus M, Marrari P, Strolin Bencdetti M and Cavalli F (1994) Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 5: 901-907
29. Volpe DA, DU DL, Zurlo MG, Mongelli N and Murphy MJ (1992) Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Invest AVu Drugs 10: 255-261
30. Weiss A, Wiskocil RL and Stobo JD (1985) The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL-2 production reflects events occurring at a pre-lranslational level. J Immunol 133: 123-128
31. Wolff I, Bench K, Beijnen J, Bruntsch U, Cavalli F, DE Jong J, Groot Y, Van Tellingen O, Wanders J and Sessa C (1996) Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given on a daily x 5 schedule. Clin Cancer Res 2: 1717-1723
32. Zucchetti M, D'lncalci M, Willems Y, Cavalli F and Sessa C (1988) Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemolher Pharmacol 22: 87-89